

## CLINICAL CAPSULES

**Intrahepatic Cholestasis of Pregnancy**

Pruritus was reduced more effectively in patients with intrahepatic cholestasis of pregnancy after treatment with ursodeoxycholic acid, according to a randomized study of 84 symptomatic patients in Lithuania.

Jurate Kondrackiene, M.D., of Kaunas University of Medicine, Kaunas, Lithuania, and colleagues found that 8-10 mg/kg daily of ursodeoxycholic acid (UDCA) outperformed 8 g daily of cholestyramine in reducing the pruritus that characterizes intrahepatic cholestasis.

Pruritus scores were reduced by 67%

with UDCA and 19% with cholestyramine; likewise, levels of serum aminotransferases and serum bile acids were markedly reduced by 78.5% and 73.8%, respectively, after UDCA, but by only 21.4% each after cholestyramine.

The study results confirm that UDCA should be used as first-line therapy for intrahepatic cholestasis, the researchers stated (*Gastroenterology* 2005;129:894-901).

**Intimate-Partner Violence Missed in ED**

Physicians may be failing to identify victims of intimate-partner violence when they

present to the emergency department, according to a study of cases brought to the prosecuting attorney in one county.

Karin Rhodes, M.D., of the department of emergency medicine at the University of Chicago and her colleague identified 964 women who were listed as victims of intimate partner violence (IPV) in cases brought to the prosecuting attorney of Kalamazoo County, Mich., during 2000.

Of these 964 women, 82% had been seen by at least one of eight EDs in the county in 1999-2001; they averaged 5.7 ED visits in that period, Dr. Rhodes reported in a poster at the annual meeting of the Society for Academic Emergency Medicine.

Even though 60% had injuries on police records, Dr. Rhodes and her associate found in a chart review that only 5.8% of the victims had a visit to an ED during 1999-2001 that corresponded to the IPV assault. The other victims either screened negative for IPV during ED visits (24.4%) or were not screened for IPV (69.8%).

**Who Undergoes Carrier Status Testing?**

Patients referred for genetic testing are more likely to agree to carrier status testing if they already have accepted an invasive procedure.

A study of 3,131 patients referred for genetic testing found that individuals were more likely to accept cystic fibrosis (CF) carrier testing and were more likely to accept both CF and fragile X syndrome (FXS) carrier testing if they underwent an invasive procedure such as amniocentesis.

"Patients who underwent such a procedure were more than twice as likely to accept both screening tests, compared with patients who had declined invasive testing," said Amy Cronister, the study's lead author and regional manager of genetic services, Genzyme Genetics, Phoenix, Ariz.

Overall, 33% of referrals agreed to carrier status testing for CF and 28% for FXS; 25% accepted CF and FXS testing; and 64% declined both. Significantly fewer (11%) accepted one test but declined the other.

The study included patients referred for prenatal genetic counseling during a 22-month period because of maternal age, positive maternal serum screening, chemical exposure, or parental anxiety. The patients were offered both CF and FXS carrier testing on the basis of population screening only.

Because they would be more likely than the general population to accept CF and FSX screening, patients with a known or suggestive family history of either disease were excluded. Additionally, because CF risk is linked to ethnicity, only patients of white and Ashkenazi Jewish backgrounds, for whom the risk of being a CF carrier is 1 in 25 people, were included.

**Oral Tocolysis Prolongs Pregnancy**

While many physicians commonly use oral tocolysis maintenance after intravenous tocolysis in patients with preterm labor because they have a clinical impression of its effectiveness, solid evidence for this practice has been lacking until recently, according to Perkin Stang, M.D., of Wayne State University, Detroit, and colleagues.

Their population-based historical cohort study suggests that patients who are not maintained on oral tocolysis are more than twice as likely to deliver prematurely as are those who do receive oral maintenance, the investigators reported in a poster presentation at the annual meeting of the Society for Maternal-Fetal Medicine.

Investigators compared 4,936 women who received oral maintenance tocolysis with a  $\beta$ -sympathomimetic agent to 4,536 who did not receive oral tocolysis, from a perinatal database in the state of Schleswig-Holstein, Germany. Women with premature rupture of membranes and medically indicated inductions before 37 weeks of gestation were excluded from the analysis.

In the oral tocolysis group, 366 patients (7%) delivered prematurely versus 1,094 patients (24%) in the control group.

—From staff reports

**FEATURING**

- Medical and Cosmetic Dermatology Applications of Topical ALA/PDT
- State of the Art – Fillers and Live Video Demonstrations
- Medi Spa Workshop
- The Future Aesthetic Injectables
- State of the Art – Botulinum Toxin Type A, Fillers, Lasers and Combinations with Live Video Demonstrations
- New Formulations in Topical Rosacea Therapy
- Live Video Demonstrations - New Rejuvenation Lasers and Radiofrequency
- Emerging Insights and New Therapeutic Opportunities for the Treatment of Acne and Atopic Dermatitis
- State of the Art – Melanoma
- Open Forum with AAD President Elect, Stephen P. Stone, M.D.
- State of the Art – Medical: Granulomatous Diseases, CTCL, Precursor Diseases, Dx, Rx and Challenging Cases
- Hyperhidrosis Treatment Updates: A Focus on Clinical and Reimbursement Issues
- Dermoscopy Workshop
- The New Isotretinoin Registry - Fitting it into your Practice
- State of the Art - Psoriasis: Current Management and Problems with David Pariser, M.D.
- Clinical Updates in the Treatment of AD with TIMS
- State of the Art - Pediatric Dermatology
- State of the Art - Advances in Cosmetic Surgery
- Surgical Pearls

**FOUNDING DIRECTORS**

Howard I. Maibach, M.D.  
University of California, San Francisco  
Henry H. Roenigk, Jr., M.D.  
Arizona Advanced Dermatology, Phoenix

**DIRECTOR OF MEETINGS**

Randall K. Roenigk, M.D.  
Mayo Clinic, Rochester

**SCIENTIFIC ADVISORY BOARD**

Terry L. Barrett, M.D.\*  
University of Texas, Southwestern  
Steven C. Bernstein, M.D.\*  
University of Montreal  
Ilona J. Frieden, M.D.\*  
University of California, San Francisco  
David J. Goldberg, M.D., J.D.\*  
Mount Sinai School of Medicine  
Kenneth E. Greer, M.D.\*  
University of Virginia  
Francisco A. Kerdel, M.D.  
University of Miami, School of Medicine  
Susan D. Laman, M.D., M.P.H.  
Mayo Clinic, Scottsdale  
Sigfrid A. Muller, M.D.  
Las Vegas Skin & Cancer Clinics  
James M. Spencer, M.D.  
Mount Sinai School of Medicine  
David L. Swanson, M.D.  
Mayo Clinic, Scottsdale  
Christopher B. Zachary, M.D., FRCP\*  
University of California, Irvine

\* indicates member of Hawaii Dermatology Seminar Planning Committee

SDEF Hawaii Dermatology Seminar is recognized by the American Academy of Dermatology for 38 hours of AAD Category 1 CME credit and may be used toward the AAD Continuing Medical Education Award.

AMA PRA Credit Designation: EOCME designates this continuing medical education activity for a maximum of 38 category 1 credits toward the AMA Physician's Recognition Award.

**EDUCATIONAL GRANT SUPPORT**

Abbott Immunology  
Allergan, Inc.  
Amgen, Inc.  
Artes Medical, Inc.  
Astellas Pharma US, Inc.  
Biogen Idec  
CollaGenex Pharmaceuticals, Inc.  
Connetics Corporation  
Coria Laboratories  
Doak Dermatologics  
DUSA Pharmaceuticals, Inc.  
Galderma Laboratories, Inc.  
Genentech, Inc.  
Johnson & Johnson  
Consumer Products Company  
La Roche-Posay  
Laboratoire Pharmaceutique  
Neocutis, Inc.  
Neutrogena  
OrthoNeutrogena  
Pierre Fabre Dermo-Cosmetique USA  
Ranbaxy Laboratories, Inc.  
SkinMedica  
Stiefel Laboratories  
Unilever Home & Personal Care USA  
Valeant Pharmaceuticals International

Jointly sponsored by



**SAVE \$300! THE 30th Annual HDS REDUCED REGISTRATION FEE HAS BEEN EXTENDED!**  
Up to Dec. 15, 2005, the HDS registration fee is \$995. From Dec. 15 - Jan. 13, 2006, the fee is \$1,295.  
For more information or to register, visit [www.sdefderm.com](http://www.sdefderm.com) or call 312.988.7700.